Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Abemaciclib for HR+/HER2- advanced or metastatic breast cancer

Ahmad Awada, MD, PhD, Institute Jules Bordet, Brussels, Belgium, talks on the use of abemaciclib, a CDK 4/6 inhibitor, for the treatment of HR+/HER2- advanced or metastatic breast cancer, highlighting results from the MONARCH 2 trial (NCT02107703). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Disclosures

Ahmad Awada, MD, PhD, has participated in an advisory role, has received institutional research grants, or has received speakers fees from Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck and Daiichi.